Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

Third Phase II Trial Initiated by Myriad For Azixa(TM)

TARRYTOWN, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today reported on new clinical advancements for Azixa(TM)* (MPC-6827), a vascular disrupting agent licensed by the Company to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Myriad announced yesterday that it has initiated a third Phase II clinical trial for Azixa in patients with non-small-cell lung cancer that has spread to the brain. The trial is designed to assess Azixa's safety profile and the extent to which it can improve the overall survival of these patients. Two additional Phase II trials for Azixa are underway in primary brain cancer and melanoma that has spread to the brain.

"We are pleased at the clinical advancement Myriad has reported on Azixa, and view it as further evidence of the commercial potential of the compound," stated Jack Talley, President and Chief Executive Officer. "We believe that the study of Azixa in this new indication affords EpiCept with an expanded opportunity to capitalize on the financial benefits associated with our agreement with Myriad, including milestone payments, sublicensing income and potentially future royalties if Azixa continues to progress successfully."

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad in 2003. The agreement requires that Myriad make future licensing, research and milestone payments to EpiCept, as well as pay a portion of any sublicensing income and pay a royalty on product sales. EpiCept will earn a milestone payment upon the dosing of the first patient in a Phas
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... , SAN DIEGO, Nov. 6 Californ...ber 9, 2009 as "No Drugs Down the Drain" week for ...ional campaign sponsored by public and private age...pharmaceutical pollution in our source water suppl...ounty customers are encouraged to drop off expired...
(Date:11/5/2009)... , SAN DIEGO, Nov. 5 Althea ...ent and manufacturing services for biopharmaceutic...ormulation Development to the company,s platform o...pointed Dr. James Matsuura, Director of Formulatio...eam of formulation and analytical scientists, alon...
(Date:11/5/2009)... , EDINA, Minn., Nov. 5 ARKRA...iabetes self-monitoring systems, today announced t...ood and Drug Administration for its new GLUCOCARD ...ew meter and strip platform, which ARKRAY will mak... expected to be a significant complement to the ex...
Breaking Medicine Technology:California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Exiqon Announces 2009 North American Grant Award Winners 50486 1Exiqon Announces 2009 North American Grant Award Winners 50486 2Exiqon Announces 2009 North American Grant Award Winners 50486 3Board Certified Cardiologist Dr Stephen Sinatra Featured on Searchbodydetox com 50483 1Board Certified Cardiologist Dr Stephen Sinatra Featured on Searchbodydetox com 50483 2Press Ganey Launches Community Image Solution 50480 1Press Ganey Launches Community Image Solution 50480 2Press Ganey Launches Community Image Solution 50480 3
.... 6 Sequella, Inc., a clinical-stage biopharmaceu...ntial, announced today that SQ109, its lead drug c...as the first drug approved for evaluation in a new...ccine Company LLC and Quintiles Transnational. The...lergy and Infectious Diseases (NIAID), National In...
...., Jan. 6 Pacira Pharmaceuticals, Inc., an,acute ...oday that enrollment,has been completed in two piv...y and efficacy of a single intraoperative administ...ged postoperative analgesia. , Results from th...throplasty (TKA) are expected to provide the prima...
Other Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3
(Date:11/8/2009)...ok called "Preventing and Healing AIDS Throug...shows that AIDS is a result of multiple, repeated ...une system stressor agents, which can be either ch...tional. , Oakland, CA (P...009, cell biologists, physicians, chemists and oth...
(Date:11/8/2009)...wire-USNewswire/ -- Today, the House of Representa..., Smith, Ellsworth and Lipinski amendment to the "...). The amendment maintains the current policy of p...efits packages that include abortion. It clarifies...ility credits and those who do not, can with their...
(Date:11/8/2009)...f H.R. 3961 to Secure the Stability of Medicare ,...atement Attributable to: J. James Rohack, M.D., Pr...: http://www.newscom.com/cgi-bin/prnh/20081209/A... House health reform bill, which will help improve... calls for swift passage of H.R. 3961 to secure th...
(Date:11/8/2009)... March of Dimes hosted t... recognize prominent individuals who are celebrati...dels for March of Dimes commitment to improve the ...ovember Prematurity Awareness Month campaign, cele...fight for preemies! ,, (Photo: http://www.new...
(Date:11/7/2009)..., David A. Cook (GA), Louis J. Goodman (TX), Palme..., CHICAGO, Nov. 7 The ... five medical society executive leaders with achie...goals and ideals of the medical profession. The aw...y making meeting in Houston. ,, (Logo: http:...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2
...th control options for men no-scalpel vasectomies ...e its popularity //there is no definitive statisti...e, as much has been stressed about the importance ...or lecturer at the University of Otago in Christch...
...ecent studies seem to confirm that oatmeal is good...f showing a direct effect of eating oatmeal on red...ut researchers say they found oatmeal foods did pr...tal cholesterol and unhealthy low-density lipoprot...
... food recall first, it is now a massive recall of ... Safety Commission (CPSC) and a leading toy manuf... million units of magnetic building sets. On...eriously injured after they swallowed the magnets....
...utives in Asia were warned Thursday of the urgent ...rming if they //want to succeed in the Western mar...roblem," said Achim Steiner, executive director of... the Environment, the first major international co...
...etting in, Shimla is running short of water supply... While the hill station with a 250,000 populatio...as only six million for distribution, according to... According to one estimate, 1.5 million gall...
...f a robotic device, resembling a caterpillar has b... performing precision heart operations without the...e Carnegie Mellon University's Robotics Institute ...wls’ at about 18cm per minute, across the heart. ...
Other Medicine News:Health News:No-scalpel Vasectomies by Skilled Surgeons may Speed Recovery 2Health News:No-scalpel Vasectomies by Skilled Surgeons may Speed Recovery 3Health News:Wholegrain Oats may Help Lower Cholesterol 2Health News:Massive Recall of Magnetic Toys in US 2Health News:Massive Recall of Magnetic Toys in US 3Health News:Asian Business Executives Urged to Be Eco-friendly 2Health News:HeartLander - Futuristic Medical Technology Takes Off 2
Sony DSR-20MD digital VTR
VISERA Imaging System
Mediscan
OxylabpO2
Medicine Products: